Literature DB >> 34029294

Association of Antidepressant Continuation in Pregnancy and Infant Birth Weight.

Paige D Wartko, Noel S Weiss, Daniel A Enquobahrie1, K C Gary Chan2, Alyssa Stephenson-Famy3, Beth A Mueller, Sascha Dublin.   

Abstract

PURPOSE: The aim of the study was to evaluate the association of antidepressant continuation in pregnancy with infant birth weight among women using antidepressants before pregnancy.
METHODS: This retrospective cohort study used electronic health data linked with state birth records. We identified singleton live births (2001-2014) to enrolled women with 1 or more antidepressant prescriptions filled 6 months or less before pregnancy, including "continuers" (≥1 antidepressant fills during pregnancy, n = 1775) and "discontinuers" (no fill during pregnancy, n = 1249). We compared birth weight, small or large for gestational age (SGA or LGA), low birth weight (LBW; <2500 g), and macrosomia (>4500 g) between the 2 groups, using inverse probability of treatment weighting to account for pre-pregnancy characteristics, including mental health conditions.
RESULTS: After weighting, infants born to antidepressant continuers weighed 71.9 g less than discontinuers' infants (95% confidence interval [CI], -115.5 to -28.3 g), with a larger difference for female infants (-106.4 g; 95% CI, -164.6 to -48.1) than male infants (-48.5 g; 95% CI, -107.2 to 10.3). For female infants, SGA risk was greater in continuers than discontinuers (relative risk [RR],1.54; 95% CI, 1.02 to 2.32). Low birth weight risk was greater in continuers with 50% or more of days covered (RR, 1.69; 95% CI, 1.11 to 2.58) and exposure in the second trimester (RR, 1.53; 95% CI, 1.02 to 2.29), as compared with discontinuers.
CONCLUSIONS: Depending on infant sex, as well as duration and timing of use, continuation of antidepressant use during pregnancy may be associated with lower infant birth weight, with corresponding increases in LBW and SGA.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34029294      PMCID: PMC8423453          DOI: 10.1097/JCP.0000000000001410

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  60 in total

1.  Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies.

Authors:  Rachel M Hayes; Pingsheng Wu; Richard C Shelton; William O Cooper; William D Dupont; Ed Mitchel; Tina V Hartert
Journal:  Am J Obstet Gynecol       Date:  2012-04-30       Impact factor: 8.661

2.  Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth.

Authors:  Janna Leigh Morrison; Caly Chien; Kenneth Wayne Riggs; Nancy Gruber; Dan Rurak
Journal:  Pediatr Res       Date:  2002-04       Impact factor: 3.756

Review 3.  A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression.

Authors:  Laura Manea; Simon Gilbody; Dean McMillan
Journal:  Gen Hosp Psychiatry       Date:  2014-09-23       Impact factor: 3.238

4.  Effects of selective serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization.

Authors:  Hélène Clabault; Denis Flipo; Jean Guibourdenche; Thierry Fournier; J Thomas Sanderson; Cathy Vaillancourt
Journal:  Toxicol Appl Pharmacol       Date:  2018-04-19       Impact factor: 4.219

5.  Outcomes of prenatal antidepressant exposure.

Authors:  Gregory E Simon; Michael L Cunningham; Robert L Davis
Journal:  Am J Psychiatry       Date:  2002-12       Impact factor: 18.112

Review 6.  Perinatal depression: a systematic review of prevalence and incidence.

Authors:  Norma I Gavin; Bradley N Gaynes; Kathleen N Lohr; Samantha Meltzer-Brody; Gerald Gartlehner; Tammeka Swinson
Journal:  Obstet Gynecol       Date:  2005-11       Impact factor: 7.661

7.  Birth weight and preterm birth in babies of pregnant women with major depression in relation to treatment with antidepressants.

Authors:  Mine Şahingöz; Goksen Yuksel; Cagatay Karsidag; Faruk Uguz; Erdem Onder Sonmez; Bilge Burcak Annagur; Ali Annagur
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

8.  Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.

Authors:  Katherine L Wisner; Dorothy K Y Sit; Barbara H Hanusa; Eydie L Moses-Kolko; Debra L Bogen; Diane F Hunker; James M Perel; Sonya Jones-Ivy; Lisa M Bodnar; Lynn T Singer
Journal:  Am J Psychiatry       Date:  2009-03-16       Impact factor: 18.112

9.  Selective serotonin re-uptake inhibitor use during pregnancy: association with offspring birth size and gestational age.

Authors:  Alexander Viktorin; Paul Lichtenstein; Cecilia Lundholm; Catarina Almqvist; Brian M D'Onofrio; Henrik Larsson; Mikael Landén; Patrik K E Magnusson
Journal:  Int J Epidemiol       Date:  2016-01-09       Impact factor: 7.196

10.  Is the Risk of Preterm Birth and Low Birth Weight Affected by the Use of Antidepressant Agents during Pregnancy? A Population-Based Investigation.

Authors:  Anna Cantarutti; Luca Merlino; Emiliano Monzani; Carlo Giaquinto; Giovanni Corrao
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

View more
  1 in total

Review 1.  Treatment of Peripartum Depression with Antidepressants and Other Psychotropic Medications: A Synthesis of Clinical Practice Guidelines in Europe.

Authors:  Sarah Kittel-Schneider; Ethel Felice; Rachel Buhagiar; Mijke Lambregtse-van den Berg; Claire A Wilson; Visnja Banjac Baljak; Katarina Savic Vujovic; Branislava Medic; Ana Opankovic; Ana Fonseca; Angela Lupattelli
Journal:  Int J Environ Res Public Health       Date:  2022-02-10       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.